Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
NCT07522606 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-08-10
Summary
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
Conditions
- Parkinson Disease
Interventions
- DRUG
-
BIA 28-6156
60mg dosage of BIA 28-6156 taken orally once daily
Sponsors & Collaborators
-
Bial R&D Investments, S.A.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- Italy
- Portugal
- Spain
- United Kingdom
Study Locations
More Related Trials
-
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
NCT01568073 ·Status: COMPLETED ·Phase: PHASE3
-
SLV308 for Treatment of Patients With Early Parkinson's Disease
NCT00269516 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
NCT02006290 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
NCT06773962 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
NCT02071810 ·Status: COMPLETED ·Phase: PHASE1
-
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
NCT04658186 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
NCT00163085 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
NCT01227655 ·Status: COMPLETED ·Phase: PHASE3
-
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
NCT00642356 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
NCT07566429 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT00148486 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of KW-6356 in Subjects With Early Parkinson's Disease
NCT02939391 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
NCT04875962 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
NCT03703570 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
NCT02847650 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
NCT02462603 ·Status: COMPLETED ·Phase: PHASE2
-
Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
NCT04810104 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
NCT01568034 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
NCT07414290 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
NCT06015841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
NCT03608371 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
NCT03000569 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease
NCT02111122 ·Status: COMPLETED ·Phase: PHASE2
-
Stalevo in Early Wearing-Off Patients
NCT00125567 ·Status: COMPLETED ·Phase: PHASE4